Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or… - The Lancet, 2011 - Elsevier
BACKGROUND: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi… - Lancet (London …, 2011 - pubmed.ncbi.nlm.nih.gov
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
L Kappos, D Li, PA Calabresi, P O'Connor… - Lancet (London …, 2011 - folia.unifr.ch
METHODS We did a multicentre, randomised, parallel, double-blind, placebo-controlled
study involving 79 centres in 20 countries. Patients aged 18-55 years with relapsing …
study involving 79 centres in 20 countries. Patients aged 18-55 years with relapsing …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or… - Lancet, 2011 - edoc.unibas.ch
Ocrelizumab in relapsing-remitting multiple sclerosis : a phase 2, randomised, placebo-controlled,
multicentre trial - edoc Logo edoc Home Policies About Statistics Contact Login …
multicentre trial - edoc Logo edoc Home Policies About Statistics Contact Login …
[引用][C] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi… - …, 2011 - researchinformation.amsterdamumc …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled,
multicentre trial — Amsterdam UMC research portal Skip to main navigation Skip to search …
multicentre trial — Amsterdam UMC research portal Skip to main navigation Skip to search …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
L Kappos, D Li, PA Calabresi, P O'Connor… - Lancet (London …, 2011 - europepmc.org
Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or… - Lancet, 2011 - thelancet.com
Background B lymphocytes are implicated in the patho genesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or… - The Lancet, 2011 - infona.pl
B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess
efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody …
efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody …
[PDF][PDF] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
L Kappos, D Li, PA Calabresi, P O'Connor, A Bar-Or… - The …, 2011 - drive.google.com
Background B lymphocytes are implicated in the patho genesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …